Cytochrome P450 Enzymes: |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.178E-14 | 6.920E-10 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 4.169E-12 | 3.535E-08 | CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 8.613E-12 | 4.689E-08 | CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.158E-11 | 1.935E-07 | CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.061E-10 | 2.889E-07 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
MF | GO:0005488; binding | GO:0020037; heme binding | 6.575E-10 | 1.193E-06 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.011E-09 | 2.919E-06 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.141E-09 | 4.023E-06 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 5.528E-09 | 6.335E-06 | CA12, CA2, CA4, CA7 |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 9.618E-09 | 8.726E-06 | CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.216E-08 | 9.455E-06 | CYP1A2, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.574E-08 | 1.142E-05 | CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.556E-08 | 2.347E-05 | CYP1A2, CYP2A13, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 6.305E-08 | 4.038E-05 | AKR1B1, CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 1.061E-07 | 5.922E-05 | CYP2A13, CYP2A6, CYP2D6 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.334E-07 | 1.271E-04 | CA12, CA2, CA4, CA7 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.625E-07 | 1.880E-04 | CYP1A2, CYP2C19, CYP2C9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.335E-07 | 2.640E-04 | CA12, CA2, CA4, CA7 |
MF | GO:0003824; catalytic activity | GO:0008389; coumarin 7-hydroxylase activity | 2.176E-06 | 9.873E-04 | CYP2A13, CYP2A6 |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 6.523E-06 | 2.785E-03 | CYP2D6, CYP3A4 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 6.523E-06 | 2.785E-03 | CA2, CA7 |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.329E-05 | 5.361E-03 | CYP1A2, MAPK1, MMP9 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.857E-05 | 7.135E-03 | CA12, CA2, CA4, CA7, L3MBTL1, MMP12, MMP2, MMP9 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 6.024E-10 | 5.028E-08 | CYP2C9; CYP2A6; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 8.521E-10 | 5.028E-08 | CYP2C9; CYP2A6; CYP2A13; CYP2D6; CYP1A2; CYP3A4 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.737E-09 | 6.833E-08 | CYP2C9; CYP2A6; CYP2A13; CYP1A2; CYP3A4; CYP2C19 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.466E-08 | 8.179E-07 | CYP2C9; CYP2A6; CYP1A2; ALDH1A1; CYP3A4 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 8.255E-08 | 1.623E-06 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 8.372E-09 | 2.470E-07 | CA12; CA2; CA4; CA7 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.987E-05 | 2.986E-04 | CYP2C9; CYP2D6; MAPK1; CYP2C19 |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.816E-05 | 3.691E-04 | MMP2; MAPK1; MMP9 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.820E-04 | 3.328E-03 | CYP2C9; CYP2A6; GAA; CYP1A2; ALDH1A1; AKR1B1; CYP2C19; CYP3A4 |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 3.915E-04 | 4.200E-03 | MMP2; MAPK1; MMP9 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 3.099E-03 | 2.353E-02 | MMP2; MAPK1; MMP9 |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.020E-03 | 1.702E-02 | CYP2A6; CYP3A4 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.637E-03 | 2.525E-02 | CYP2C9; CYP2C19 |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 7.675E-03 | 4.767E-02 | MMP2; MAPK1 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 8.611E-04 | 7.816E-03 | GAA; AKR1B1 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.191E-03 | 2.353E-02 | CYP1A2; CYP3A4 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.742E-03 | 3.108E-02 | CA2; CYP3A4 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 5.040E-04 | 4.956E-03 | CA2; CA4 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.025E-05 | 2.986E-04 | CYP2A6; CYP1A2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2 |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | OPRK1 |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2 |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | OPRK1 |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | OPRK1 |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12 |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; MMP12 |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | OPRK1; MAPT |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12 |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | OPRK1 |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1 |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRK1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1; MMP9; MMP2 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | OPRK1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
NA: NA | Edema | NA | CA2 |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | OPRK1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | OPRK1 |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
C00-D49: Neoplasms | Cancer | C00-C96 | MAPK1; MMP9; MMP2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Opiate dependence | F11 | OPRK1 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |